SCHEMBL23057573

SCHEMBL23057573

CC(C)C(=O)Oc1c(F)c(F)cc(P)c1F

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ELANE P08246 2/20 0.36
▸ KDM4E B2RXH2 2/20 0.35
▸ ALDH1A1 P00352 1/20 0.35
▸ MAPT P10636 1/20 0.35
▸ HTT P42858 1/20 0.35
▸ ALOX15 P16050 1/20 0.34
▸ GAA P10253 2/20 0.33
▸ CES2 O00748 2/20 0.33
▸ CES1 P23141 2/20 0.33
▸ ADRB2 P07550 1/20 0.31
▸ ADRA2A P08913 1/20 0.31
▸ DRD2 P14416 1/20 0.31
▸ ADRA2C P18825 1/20 0.31
▸ DRD1 P21728 1/20 0.31
▸ ADRA1A P35348 1/20 0.31
▸ DRD3 P35462 1/20 0.31
▸ CASP3 P42574 2/20 0.31
▸ CHRNA1 P02708 1/20 0.30
▸ CHRNG P07510 1/20 0.30
▸ CHRNB1 P11230 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23057564 0.87 ELANE (0.33) ELANEALOX15GAA
SCHEMBL12213944 0.87 MAPT (0.42) ELANEKDM4EALDH1A1MAPTHTT
SCHEMBL22381468 0.85 MAPT (0.37) ELANEKDM4EALDH1A1MAPTHTT
SCHEMBL22381449 0.83 GAA (0.37) ELANEALOX15GAAADRB2ADRA2A
SCHEMBL22381458 0.82 ELANE (0.33) ELANEKDM4EALDH1A1MAPTHTT
SCHEMBL19105004 0.81 ELANE (0.37) ELANEKDM4EALDH1A1MAPTHTT
SCHEMBL11915792 0.75 ELANE (0.42) ELANEALOX15GAAADRB2ADRA2A
SCHEMBL21503687 0.74 ELANE (0.48) ELANEALOX15CES2CES1ADRB2
SCHEMBL17662449 0.74 ELANE (0.40) ELANEALDH1A1ALOX15GAACES2
SCHEMBL27494903 0.73 MAPT (0.40) KDM4EALDH1A1MAPTHTTCES2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11793895-B2 Residualizing linkers and uses thereof CENTRE FOR PROBE DEVELOPMENT AND COMMERCIALIZATION 2023-10-24 — — US disclosed
US-20210060190-A1 RESIDUALIZING LINKERS AND USES THEREOF CENTRE FOR PROBE DEVELOPMENT AND COMMERCIALIZATION (CA) 2021-03-04 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210060190-A1 RESIDUALIZING LINKERS AND USES THEREOF CD44, CD47, MTCL3 ELANE 3316/4885KDM4E 937/4885ALDH1A1 619/4885
US-11793895-B2 Residualizing linkers and uses thereof CD44, CD47, MTCL3 ELANE 3316/4885KDM4E 937/4885ALDH1A1 619/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback